Literature DB >> 14559405

Murine models to investigate pharmacological compounds acting as ligands of PPARs in dyslipidemia and atherosclerosis.

Anne Tailleux1, Gérard Torpier, Hafid Mezdour, Jean-Charles Fruchart, Bart Staels, Catherine Fiévet.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14559405     DOI： 10.1016/j.tips.2003.08.001

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN： 0165-6147            Impact factor:   14.819


× No keyword cloud information.
  4 in total

1.  Peroxisome proliferator-activated receptor-alpha gene level differently affects lipid metabolism and inflammation in apolipoprotein E2 knock-in mice.

Authors:  Fanny Lalloyer; Kristiaan Wouters; Morgane Baron; Sandrine Caron; Emmanuelle Vallez; Jonathan Vanhoutte; Eric Baugé; Ronit Shiri-Sverdlov; Marten Hofker; Bart Staels; Anne Tailleux
Journal:  Arterioscler Thromb Vasc Biol       Date:  2011-04-07       Impact factor: 8.311

2.  The thyroid hormone mimetic compound KB2115 lowers plasma LDL cholesterol and stimulates bile acid synthesis without cardiac effects in humans.

Authors:  Anders Berkenstam; Jens Kristensen; Karin Mellström; Bo Carlsson; Johan Malm; Stefan Rehnmark; Neeraj Garg; Carl Magnus Andersson; Mats Rudling; Folke Sjöberg; Bo Angelin; John D Baxter
Journal:  Proc Natl Acad Sci U S A       Date:  2007-12-26       Impact factor: 11.205

3.  Simvastatin reverses the hypertension of heterozygous mice lacking cystathionine beta-synthase and apolipoprotein A-I.

Authors:  Ricardo Carnicer; María A Navarro; Natalia Guillén; José M Arbonés-Mainar; Joaquín C Surra; Sergio Acín; Jesús Osada
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-01-26       Impact factor: 3.000

4.  Peroxisome proliferator activated receptors and lipoprotein metabolism.

Authors:  Sander Kersten
Journal:  PPAR Res       Date:  2008       Impact factor: 4.964
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.